Latest news and press releases
Bracco Diagnostics Inc. Branded Max 3™ received FDA 510(k) clearance
Bracco Diagnostics Inc. Branded Max 3TM, a Rapid Exchange and Syringeless Injector, received FDA 510(k) clearance adding evolving innovation in Magnetic Resonance Imaging (MRI) and its product portfolio.
ColoWatch® and Bracco Diagnostics Partner to Expand the Availability of Virtual Colonoscopy for the Early Detection of Colon and Rectal Cancer
To learn more, visit Bracco’s booth #3300 at the Radiological Society of North America (RSNA) 2024 Annual Meeting, to be held from December 1-5 in Chicago, Illinois
Bracco Diagnostics Inc. Achieves 1 Million Injections with VUEWAY® (gadopiclenol) solution for injection
Bracco Diagnostics Inc. is proud to announce that its most recently FDA-approved magnetic resonance imaging (MRI) agent, VUEWAY® (gadopiclenol) solution for injection, has reached over one million patient injections at over 480 customer sites.
Bracco Diagnostics Inc. Showcases Innovations and More at RSNA 2024 Annual Meeting
This year, Bracco’s activities at RSNA are captured by the theme, “Our journey to the future continues today, together”—underscoring Bracco’s commitment to partnering with its customers to advance the practice of radiology.
Bracco Diagnostics and Subtle Medical Announce FDA Clearance of AiMIFY™ Software
Bracco Diagnostics Inc. and Subtle Medical, Inc. are thrilled to announce that their collaborative AI-powered software, AiMIFYTM, has received FDA clearance as a Class II software as a medical device (SaMD) for magnetic resonance imaging (MRI) of the brain.
Join Bracco at RSNA 2024
Explore the Bracco Booth #3300 as Bracco Diagnostics Inc. showcases its innovations and more at the 2024 Radiological Society of North America Annual Congress.
Bracco Diagnostics Inc. Introduces CitraClear™ to the Healthcare Community
Bracco Diagnostics Inc. (BDI) proudly unveils CitraClearTM, a pre-procedure hydration beverage designed with patients in mind.
Bracco Diagnostics Inc. Announces Update on Product Portfolio
Strategic decisions enable Bracco to serve better the needs of healthcare providers and patients with its enhanced pipeline offering.
Bracco and SABI Announce Continued Partnership of the SABI Bracco Mentorship Program
Bracco is proud to renew its three-year unrestricted educational grant commitment as the sole partner of the SABI Mentorship Program. The objective of the program is to support the career growth and personal development of SABI members.
Applied Radiology Announces Recipients of “Leaders on the Horizon” Program
Sponsorship of “Leaders on the Horizon” program just one component of the “Bracco Under 40” training program, elevating next generation of radiologists. Program has expanded globally, now includes all diagnostic imaging modalities.
BRACCO INVITES YOU @ RSNA 2023
Bracco Diagnostics Showcases Innovation and Collaborative Vision at RSNA 2023 Annual Meeting.
Data Reinforcing Efficacy and Safety of Gadopiclenol in Contrast-Enhanced MRI of Certain Body Regions Published in Radiology
Our New Iodine Recollection Pilot and Re.Viva
Re.Viva works to capture and redeploy used substances in the positive momentum of the circular economy: the Bracco Iodine Recollection Pilot
ACR Classifies Gadopiclenol as a Group II Agent
Gadopiclenol solution for injection and Gadopiclenol Pharmacy Bulk Package are available for use in the U.S. following the market launch in February 2023.
Bracco’s VUEWAY™ (gadopiclenol) injection now in hospitals
Preeminent Hospitals and Medical Practices Nationwide Lead in Patient Care with First Use of Bracco’s VUEWAY™ (gadopiclenol) solution for injection for MRI.
Efficacy and Safety of Gadopiclenol
The results of the multicenter, multinational PICTURE clinical trial demonstrate that 0.05 mmol/kg gadopiclenol provides similar morphologic information about CNS lesions and greater contrast enhancement compared with 0.1 mmol/kg gadobutrol.
New Survey Finds 55% of Radiologists Have Concerns About Contrast Agent Availability
Bracco Diagnostics Inc. releases data from 200 radiologists on the current state of their field
Temporary importation of Iomeron® (iomeprol injection) to address drug shortage issues
Due to a prior shortage of iodinated contrast media indicated for intravascular use in the U.S. market, Bracco Diagnostics Inc.
Join us celebrating our new website
We are thrilled to open the doors of our “digital house” created by our people and inhabited by our stories
Bracco Announces the 2022 “Leaders on the Horizon” Residency Program Recipients
Radiology residents receive scholarship, research publication in Applied Radiology supplement, and invite to RSNA reception.
Drivers and barriers: Innovation in healthcare
Alberto Spinazzi, Bracco Chief Medical and Regulatory Officer, answers some of these questions by illustrating future trends and the importance of prevention for human health.
Talking Images podcast: The sustainable way – voices of action
Talking Images podcast: The sustainable way – voices of action. What do environmental sustainability and sustainable future mean?
FDA approves Gadopiclenol injection for the U.S. market
Bracco Announces FDA Approval of Gadopiclenol Injection, a New Macrocyclic High-Relaxivity Gadolinium-Based Contrast Agent which will be commercialized as VUEWAY™ (gadopiclenol) injection and VUEWAY™ (gadopiclenol) Pharmacy Bulk Package by Bracco.
BIPSO further strengthens environmental protection
BIPSO sets the course for sterile contrast media production according to the latest environmental standards.
Bracco’s digital historical archive goes online
The astounding Bracco story unfolds across archives that have been thematically divided into five sections: Family, Company, Innovation, Sustainability, and Culture.
Gadopiclenol: another milestone achieved
Bracco Imaging and Guerbet have a worldwide collaboration on Gadopiclenol, an investigational macrocyclic gadolinium-based contrast agent (GBCA).
The Bracco Fellowships are back
95 grants to celebrate Bracco’s 95th Anniversary
The US shortage crisis: Bracco Imaging’s CEO statement on New York Times
The US shortage crisis: Bracco Imaging’s CEO statement on New York Times
Cathena has ended: a customised nanomedicine project
A new customised nanomedicine project to fight cancer, a new therapy that includes pre-treating
First Ukrainian family is welcomed in housing provided by Bracco near the Cesano plant
They have left the war in Ukraine behind and have been welcomed in Italy by the Bracco Group in collaboration with the Town of Cesano and the local community.
Bracco Foundation meets Shaharzad Akbar, not to forget the Afghan women
Shaharzad Akbar arrived from Rome where she had provided testimony during a meeting of Italy’s Chamber of Deputies and Senate Joint Committee on Foreign Affairs.
The world cannot grow without gender equality
Some of the goals in a Policy Paper drafted by the B20 Special Initiative on Women’s Empowerment.
Diana Bracco and Gianvito Vilé, winner of the Felder Award, appear at Trieste Next Festival
Trieste Next Festival: Diana Bracco and Gianvito Vilé talk about scientific research and the brain drain.
The Bracco Foundation: ten years in the name of culture, science and social engagement
The Bracco Foundation: ten years in the name of culture, science and social engagement.
Sight and sound: the latest way to share radiology reports
Stay plugged in to the latest developments—for radiologists, imagine: rather than generating a text report for a referring physician, you could show them your workstation directly.
Trailblazing AI tool tracks cancer via radiology reports
Is AI the elephant in the radiology suite? A 2019 report from the Dana-Farber Cancer Institute showcased an artificial intelligence tool that performed as well as human reviewers—and much more rapidly.
Nuclear medicine poised to reach $12 billion by 2025
It is projected that nuclear medicine will continue its growth, from $6.5 billion in 2017 to $12.41 billion in 2025. What kind of innovation is fueling this near doubling in market impact?
Media contacts
If you are a journalist and you need more information about Bracco Imaging Group.
Bracco Imaging S.p.A.
Media Relations
Via Egidio Folli 50, 20134 - Milan, Italy
Tel. +39 (02) 21772279
Contact by email: [email protected]
Contact us
Please fill out the form below and we will get back to you